|
I'm not sure http://santafaz-cordoba.es/samedicalorghpcsa-6900.pdf#dry samedical.org/hpcsa
"CMS appears to be challenging the value of an adjunctive tool that can assist physicians in making a more informed diagnosis for patients with cognitive impairment. Restricting coverage could hinder a timely and accurate diagnosis, which is in conflict with the advice of Alzheimer's Disease experts and with the administration's National Alzheimer's Project Act," said Daniel Skovronsky, president and CEO of Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Eli Lilly and Company.
|